ES2676905T3 - Derivados de piridazina para su uso en la prevención o tratamiento de una trastorno atáxico - Google Patents

Derivados de piridazina para su uso en la prevención o tratamiento de una trastorno atáxico Download PDF

Info

Publication number
ES2676905T3
ES2676905T3 ES15709324.6T ES15709324T ES2676905T3 ES 2676905 T3 ES2676905 T3 ES 2676905T3 ES 15709324 T ES15709324 T ES 15709324T ES 2676905 T3 ES2676905 T3 ES 2676905T3
Authority
ES
Spain
Prior art keywords
hydroxypyridazin
ethyl
hydroxy
trifluoromethyl
pyridazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15709324.6T
Other languages
English (en)
Spanish (es)
Inventor
Sarah Almond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50554599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2676905(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2676905T3 publication Critical patent/ES2676905T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES15709324.6T 2014-03-06 2015-03-06 Derivados de piridazina para su uso en la prevención o tratamiento de una trastorno atáxico Active ES2676905T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201403944 2014-03-06
GBGB1403944.0A GB201403944D0 (en) 2014-03-06 2014-03-06 New use
PCT/GB2015/050654 WO2015132608A1 (en) 2014-03-06 2015-03-06 Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder

Publications (1)

Publication Number Publication Date
ES2676905T3 true ES2676905T3 (es) 2018-07-26

Family

ID=50554599

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15709324.6T Active ES2676905T3 (es) 2014-03-06 2015-03-06 Derivados de piridazina para su uso en la prevención o tratamiento de una trastorno atáxico

Country Status (32)

Country Link
US (1) US20170014407A1 (OSRAM)
EP (1) EP3113778B1 (OSRAM)
JP (1) JP6510549B2 (OSRAM)
KR (1) KR20160126081A (OSRAM)
CN (1) CN106102743A (OSRAM)
AU (1) AU2015225954B2 (OSRAM)
CA (1) CA2940342A1 (OSRAM)
CL (1) CL2016002151A1 (OSRAM)
CY (1) CY1120573T1 (OSRAM)
DK (1) DK3113778T3 (OSRAM)
EA (1) EA036438B1 (OSRAM)
ES (1) ES2676905T3 (OSRAM)
GB (1) GB201403944D0 (OSRAM)
GE (1) GEP20196984B (OSRAM)
HR (1) HRP20181082T1 (OSRAM)
IL (1) IL247435A0 (OSRAM)
LT (1) LT3113778T (OSRAM)
MA (1) MA39315A1 (OSRAM)
MX (1) MX2016010524A (OSRAM)
MY (1) MY202127A (OSRAM)
PH (1) PH12016501751A1 (OSRAM)
PL (1) PL3113778T3 (OSRAM)
PT (1) PT3113778T (OSRAM)
RS (1) RS57594B1 (OSRAM)
SG (1) SG11201607106YA (OSRAM)
SI (1) SI3113778T1 (OSRAM)
SM (1) SMT201800367T1 (OSRAM)
TR (1) TR201809537T4 (OSRAM)
TW (1) TW201534591A (OSRAM)
UA (1) UA123352C2 (OSRAM)
WO (1) WO2015132608A1 (OSRAM)
ZA (1) ZA201604611B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
PT3137456T (pt) 2014-04-29 2021-08-06 Fmc Corp Herbicidas de piridazinona
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
WO2019005484A1 (en) 2017-06-30 2019-01-03 Fmc Corporation 4- (3,4-DIHYDRONAPHTH-1-YL OR 2H-CHROMEN-4-YL) -5-HYDROXY-2H-PYRADIZIN-3-ONES AS HERBICIDES
CN112569217B (zh) * 2019-09-30 2022-04-22 厦门大学 戊酸衍生物在治疗遗传性小脑共济失调中的应用
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
JP2024508860A (ja) 2021-03-01 2024-02-28 武田薬品工業株式会社 認知機能障害の処置のためのルバダキシスタットの使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067545B1 (en) * 1998-06-10 2006-06-27 Meiji Seika Kaisha Ltd. Remedies for spinocerebellar ataxia and compositions for treating spinocerebellar ataxia
WO2003047558A2 (en) * 2001-12-03 2003-06-12 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
JO3115B1 (ar) * 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao

Also Published As

Publication number Publication date
CL2016002151A1 (es) 2016-12-30
TW201534591A (zh) 2015-09-16
AU2015225954A1 (en) 2016-07-07
CA2940342A1 (en) 2015-09-11
PT3113778T (pt) 2018-07-11
SMT201800367T1 (it) 2018-09-13
PH12016501751A1 (en) 2017-02-06
ZA201604611B (en) 2017-09-27
IL247435A0 (en) 2016-11-30
HRP20181082T1 (hr) 2018-09-07
EA036438B1 (ru) 2020-11-11
EP3113778A1 (en) 2017-01-11
MX2016010524A (es) 2016-10-31
SI3113778T1 (en) 2018-08-31
RS57594B1 (sr) 2018-11-30
JP2017507156A (ja) 2017-03-16
PL3113778T3 (pl) 2018-11-30
EA201691566A1 (ru) 2016-12-30
MY202127A (en) 2024-04-05
KR20160126081A (ko) 2016-11-01
WO2015132608A1 (en) 2015-09-11
MA39315A1 (fr) 2017-09-29
CY1120573T1 (el) 2019-07-10
TR201809537T4 (tr) 2018-07-23
GB201403944D0 (en) 2014-04-23
CN106102743A (zh) 2016-11-09
US20170014407A1 (en) 2017-01-19
UA123352C2 (uk) 2021-03-24
SG11201607106YA (en) 2016-09-29
GEP20196984B (en) 2019-06-25
LT3113778T (lt) 2018-08-27
EP3113778B1 (en) 2018-06-06
JP6510549B2 (ja) 2019-05-08
DK3113778T3 (en) 2018-07-30
AU2015225954B2 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
ES2676905T3 (es) Derivados de piridazina para su uso en la prevención o tratamiento de una trastorno atáxico
US12201631B2 (en) Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and fragile X syndrome
US20220040150A1 (en) Intravenous dmt administration method for dmt-assisted psychotherapy
JP5875191B2 (ja) Ｃｍｔ及び関連障害を処置するための新たな組成物
TWI291871B (en) Pharmaceutical compositions and use of amphetamine compounds for improving memory and learning
JP5605659B2 (ja) 細胞保護剤
ES2323451T3 (es) Tratamiento para el trastorno de hiperactividad con deficit de atencion.
Liu et al. A dystonia-like movement disorder with brain and spinal neuronal defects is caused by mutation of the mouse laminin β1 subunit, Lamb1
US20220273662A1 (en) Use of sildenafil and rock inhibitors for treating stroke or sequelae following stroke
Barr et al. Repeated electroconvulsive shock attenuates the depressive-like effects of d-amphetamine withdrawal on brain reward function in rats
Oksman et al. Behavioural and neurochemical response of α-synuclein A30P transgenic mice to the effects of L-DOPA
HK1230925A1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
EP4203948A1 (en) Compositions and uses thereof
Gombos et al. Long-term enhancement of entorhinal-dentate evoked potentials followingmodified'ECS in the rat
US20230062537A1 (en) Therapy of oxygen pulses for treating neurodegenerative disorders such as Parkinson Disease (PD), Alzheimer’s Disease (AD), Amiotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND) and other dementias, and Lymphedema, Arthritis and Depression
Yang A study of ocular dominance plasticity: probing the molecular mechanisms and exploring its effect on functional connectivity
EP4208161A1 (en) Compositions and uses thereof
Klisko Targeting Muscarinic Receptor Subtypes as a Therapeutic Approach in Dystonia and Parkinson's Disease
Wortinger What happens after successful CPCR.
Hunter Glutamate and escape performance in a neurometabolic stress conception of helplessness
Sanberg An animal model of Huntington’s disease: behavioral, pharmacological and morphological changes following intrastriatal injections of kainic acid
Heinz et al. How much fear is in anxiety?
McGraw NEOCORTICAL AND OTHER MODULATING INFLUENCES ON THE'IMMOBILITY REFLEX'